We bring you our round-up of the latest legal and commercial issues for life sciences businesses.
In this issue we provide an update on the legal consequences for life sciences businesses following the publication of the EU-UK Trade and Co-operation Agreement.
We also look at COVID-19 vaccine related crime and the significant risks that counterfeit pharmaceutical products pose to public health.
Finally, the latest entries to our Life Sciences Legal A to Z provide a brief overview of patents and pay for delay cases.
A link to the web version of this email update is available here. If you would like to receive these updates via email, please subscribe.
Charlotte Tillett
Gustaf Duhs